Generali Investments CEE investicni spolecnost a.s. Purchases Shares of 10,000 Takeda Pharmaceutical Company Limited (NYSE:TAK)

Generali Investments CEE investicni spolecnost a.s. purchased a new stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 10,000 shares of the company’s stock, valued at approximately $132,000.

Other hedge funds have also added to or reduced their stakes in the company. Public Employees Retirement System of Ohio acquired a new stake in Takeda Pharmaceutical during the 3rd quarter valued at $601,000. QRG Capital Management Inc. lifted its holdings in shares of Takeda Pharmaceutical by 16.8% during the fourth quarter. QRG Capital Management Inc. now owns 329,644 shares of the company’s stock worth $4,364,000 after buying an additional 47,490 shares in the last quarter. Verition Fund Management LLC acquired a new stake in shares of Takeda Pharmaceutical during the third quarter worth $1,533,000. HighTower Advisors LLC lifted its holdings in shares of Takeda Pharmaceutical by 199.5% during the third quarter. HighTower Advisors LLC now owns 122,587 shares of the company’s stock worth $1,744,000 after buying an additional 81,653 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of Takeda Pharmaceutical during the third quarter worth $957,000. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Up 1.2 %

TAK opened at $15.18 on Monday. Takeda Pharmaceutical Company Limited has a fifty-two week low of $12.57 and a fifty-two week high of $15.22. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31. The company has a market capitalization of $48.29 billion, a P/E ratio of 37.94, a P/E/G ratio of 0.24 and a beta of 0.46. The stock has a fifty day moving average of $13.59 and a 200-day moving average of $13.90.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. On average, equities analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.